Gales Ferry, CT, United States of America

Mark Edward Flanagan

This inventor holds 47 USPTO granted patents and 10 published patent applications, plus 10 CIPO patents and 11 EPO patents, primarily in GLP-1 Receptor Agonists. Top assignees: Pfizer Corporation, Witco Corporation, Pfizer Products Inc.. Active years: 1986-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark Edward Flanagan. Retrieved from https://idiyas.com/inventor/mark-edward-flanagan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 47 (Patent Applications = 10)

% Patents Active = 76.6

CIPO Patents = 10 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 14)

Average Co-Inventor Count = 4.8

ph-index = 15

Forward Citations = 670(Granted Patents)

Location History:

Pittsburgh, PA (US) (1986)
Ft. Collins, CO (US) (1991 - 1993)
Gales Ferry, CT (US) (2003 - 2024)

Company Filing History:

4. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1986-2026

Loading Chart...

Areas of Expertise:

GLP-1 Receptor Agonists

Pyrrolo Compounds

Antibody Drug Conjugates

NASH Treatment

NAFLD Treatment

Benzodioxol

Heteroaryl Sulfone

Macrolides

Chiral Salt Resolution

Pyrimidine Derivatives

Pyrimidine Compounds

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12611401 - Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases (2026-04-28),

2. 12378230 - GLP-1 receptor agonists and uses thereof (2025-08-05),

3. 12331041 - GLP-1 receptor agonists and uses thereof (2025-06-17),

4. 12319669 - GLP-1 receptor agonists and uses thereof (2025-06-03),

5. 12077533 - Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides (2024-09-03),

6. 11858916 - GLP-1 receptor agonists and uses thereof (2024-01-02),

7. 11802121 - GLP-1 receptor agonists and uses thereof (2023-10-31),

8. 11712480 - Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates (2023-08-01),

9. 11512070 - GLP-1 receptor agonists and uses thereof (2022-11-29),

10. 11111242 - Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides (2021-09-07),

11. 10934279 - GLP-1 receptor agonists and uses thereof (2021-03-02),

12. 10851081 - GLP-1 receptor agonists and uses thereof (2020-12-01),

13. 10703756 - Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof (2020-07-07),

14. 10683281 - GLP-1 receptor agonists and uses thereof (2020-06-16),

15. 10676465 - GLP-1 receptor agonists and uses thereof (2020-06-09),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I'm eager to provide you with an article about inventor Mark Edward Flanagan.

Title: The Innovative Journey of Mark Edward Flanagan

Introduction: Mark Edward Flanagan is a prominent inventor hailing from Gales Ferry, CT in the US. He has made significant contributions to the field of pharmaceuticals through his numerous patented inventions.

Latest Patents: Among Mark Edward Flanagan's impressive portfolio of 38 patents, his recent work includes patents related to GLP-1 receptor agonists and their applications. These patents involve compositions such as 6-carboxylic acids of benzimidazoles and various benzimidazole derivatives, serving as GLP-1R agonists for medical uses.

Career Highlights: Mark Edward Flanagan has garnered experience and expertise by working with prestigious companies like Pfizer Corporation and Pfizer Products Inc. His tenure at these institutions has shaped his innovative mindset and refined his skills in the pharmaceutical industry.

Collaborations: Throughout his career, Mark Edward Flanagan has collaborated with talented individuals such as Todd A. Blumenkopf and Michael John Munchhof. These collaborations have led to the development of novel pharmaceutical solutions and advancements in the field of medicine.

Conclusion: Mark Edward Flanagan stands as a remarkable inventor with a penchant for creating groundbreaking solutions in the pharmaceutical domain. His dedication to innovation and his collaborative spirit have cemented his position as a notable figure in the world of patents and inventions.

I hope this article provides insight into the impressive journey of inventor Mark Edward Flanagan. If you have any more requests or need further information, feel free to ask!

Profile summary based on public USPTO records.